June 2008
Cardiology Today;Jun2008, Vol. 11 Issue 6, p49
The article offers products and service news briefs on cardiology field as of June 2008. The U.S. Food & Drug Administration (FDA) approved the new application of SURECardio Prospective and Variable Helical Pitch from Toshiba. Integrium launched a process designed to deliver consistent results on their clinical trial programs, Integrium Clinical Excellence. Philips launched the IntelliVue mobile viewer application for receiving electronic patient alerts and allows patient information access by physicians from anywhere in the hospital.


Related Articles

  • Acorn gets FDA okay for new trial of CorCap device. Pedersen, Amanda // Cardiovascular Device Update;Jun2007, Vol. 13 Issue 6, p10 

    The article reports on the plan of Acorn officials to remain confident and committed to working with the U.S. Food and Drug Administration (FDA) to win eventual approval for its CorCap cardiac support device. The company is nearing to get the FDA approval after it reached an agreement with the...

  • FDA Begins Product Approval Initiative. Lewis, Carol // FDA Consumer;May/Jun2003, Vol. 37 Issue 3, p10 

    Provides information on the reform plan of the U.S. Food and Drug Administration to the medical products approval process. Causes of delay in product approvals; Information on products with multiple reviews; Significance of clarifying the requirements for approval.

  • Recruitment Drivers. Goldfarb, Jeff // Applied Clinical Trials;May2012, Vol. 21 Issue 5, Special section p2 

    The article focuses on the struggling condition in the U.S. cancer trial recruitment, exploring patient-oncologist interactions. It presents a survey wherein findings reveal that increased perceived benefit rather than increased knowledge may be the best way to increase patient enrollment in...

  • Characteristics of Pivotal Trials and FDA Review of Innovative Devices. Rising, Joshua P.; Moscovitch, Ben // PLoS ONE;Feb2015, Vol. 10 Issue 2, p1 

    When patients lack sufficient treatment options for serious medical conditions, they rely on the prompt approval and development of new therapeutic alternatives, such as medical devices. Understanding the development of innovative medical devices, including the characteristics of premarket...

  • FDA okays Spectranetics' halt of CELLO trial.  // Medical Technology & Devices Week;3/19/2007, Vol. 5 Issue 12, p5 

    The article reports that the U.S. Food and Drug Administration has given Spectranetics the go-ahead to halt its CELLO trial. The product is designed to explore use of the company's TURBO-Booster product in clearing blockages in the superficial femoral artery. TURBO-Booster is a laser/catheter...

  • FDA Guidance Gives Clarity to Medical Device Firms. Jaeger, Jaclyn // Compliance Week;Jun2014, Vol. 11 Issue 125, p14 

    The article presents information on the Food and Drug Administration's new guidance for pharmaceutical and medical device companies. The guidance is on two topics, distributing documents on the unauthorized uses of drugs and medical devices, and soliciting feedback during the process for getting...

  • FDA ready to set standards for contrast sensitivity testing. Meszaros, Liz // Ophthalmology Times;4/15/2004, Vol. 29 Issue 8, p21 

    Anticipates the approval of the U.S. Food and Drug Administration to contrast sensitivity testing in clinical trials. Elimination of the confusion about contrast sensitivity; Identification of contrast sensitivity as an accurate way to quantify vision; Proponents for using contrast sensitivity...

  • Vasogen's design for heart failure trial gets FDA questions. Yoffee, Lynn // Cardiovascular Devices & Drugs;Mar2008, Vol. 14 Issue 3, p22 

    The article reports on the concerns raised by the U.S. Food and Drug Administration (FDA) on how Vasogen plans to recruit patients for its Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM II) trial, intended to support an application for U.S. market...

  • Panel says 'no' to non-RCTs, this time for carotid stenting. McCarty, Mark // Cardiovascular Device Update;Nov2007, Vol. 13 Issue 11, p14 

    This article reports on the decision of the circulatory systems advisory committee of the U.S. Food and Drug Administration not to support the idea to grant device makers greater leeway in the use of clinical trials other than the gold standard of randomized, controlled trials. The panel...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics